文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

间充质干细胞移植治疗2019冠状病毒病的可能性

[Possibility of mesenchymal stem cell transplantation in the treatment of coronavirus disease 2019].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论间充质干细胞因具有免疫调节与再生修复功能,作者认为可考虑作为治疗COVID-19的新有效方法,但本文为机制分析与可行性探讨,未报告临床结局。

本文为综述性文章,分析2019新型冠状病毒的主要致病机制及其发展为急性呼吸窘迫综合征(ARDS)和脓毒症的过程。文章指出,2019-nCoV感染可导致炎症,并可能恶化为ARDS和脓毒症,已成为其主要死亡并发症,因此使用抗病毒与对症治疗并减轻炎症可获得更好疗效。间充质干细胞不仅具有显著的免疫调节功能,还能发挥再生与修复作用、修复受损肺脏,故作者认为可考虑作为治疗COVID-19的新有效方法。文章结合间充质干细胞研究现状,探讨其治疗COVID-19的意义与可行性,为当前及未来临床治疗提供理论依据。

要点

  • 2019-nCoV感染可导致炎症,并可能恶化为ARDS和脓毒症,后者已成为其主要死亡并发症。
  • 作者认为,使用抗病毒与对症治疗并减轻炎症可获得更好的治疗效果。
  • 间充质干细胞具有显著的免疫调节功能,并发挥再生与修复作用,可修复受损肺脏。
  • 作者认为间充质干细胞可考虑作为治疗COVID-19的新有效方法。
  • 本文为机制分析与可行性探讨,旨在为当前及未来临床治疗提供理论依据。

研究设计与关键结果

  • 本文分析2019-nCoV的主要致病机制及其发展为ARDS的过程,并结合间充质干细胞研究现状,探讨其治疗COVID-19的意义与可行性。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,间充质干细胞可考虑作为治疗COVID-19的新有效方法。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

2019 Novel coronavirus (2019-nCoV) infection has caused a global pandemic. Although researchers have carried out a lot of research on 2019-nCoV, analyzed the molecular structure and conducted evolutionary tree analysis, there is still insufficient understanding of its specific pathogenic mechanism, resulting in the lack of specific and effective therapeutic drugs and method. 2019-nCoV infection can cause inflammation and may deteriorate to acute respiratory distress syndrome (ARDS) and sepsis, which have become the main complication of its death. Therefore, using antiviral and symptomatic treatment with inflammation reduction can have a better therapeutic effect. Mesenchymal stem cells (MSCs) not only have a significant immune-regulation function, but also play a role in regeneration and repair, repairing damaged lungs, so they can be considered as a new effective method for the treatment of coronavirus disease 2019 (COVID-19). This article analyzes the main pathogenic mechanism of 2019-nCoV, and the process of developing into ARDS, combined with the research status of MSCs, to explore its significance and feasibility for the treatment of COVID-19. Finally, it will provide a substantial theoretical basis for clinical treatment now and in the future.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Yao M, Chen Z, He X, et al. [Possibility of mesenchymal stem cell transplantation in the treatment of coronavirus disease 2019]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 33081907. doi:10.3760/cma.j.cn121430-20200506-00623

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。